Menu
Close
About Us
Company Overview
Leadership
Board of Directors
Business Advisors
Scientific Advisory Board
Corporate Governance
Our Focus
COVID-19 and CVD
Acute Myocarditis
Heart Failure
R&D Partners
Our Science
Resources
Products
Investors
Events & Presentations
Press Releases
Analyst Coverage
Stock Information
Filings & Financials
AGM
Contact Us
News
Cardiol Therapeutics to Participate in Upcoming Virtual Investor Conferences
January 07, 2021
Cardiol Therapeutics Announces Completion of Phase I Clinical Study of CardiolRx™
December 22, 2020
Cardiol Therapeutics Appoints Worldwide Clinical Trials as CRO for the Company’s Phase II/III Outcomes Trial in High-risk Patients Hospitalized with COVID-19
December 15, 2020
Cardiol Therapeutics’ Cortalex™ CBD Now Available Exclusively Online at Medical Cannabis by Shoppers Inc.
October 20, 2020
Cardiol Therapeutics Receives FDA Approval for Investigational New Drug (IND) Application for Phase II/III COVID-19 Trial
September 25, 2020
Cardiol Therapeutics to Present at the H.C. Wainwright Virtual 22nd Annual Global Investment Conference
September 15, 2020
Cardiol Therapeutics Initiates Health Canada Approved Phase 1 Clinical Study of CardiolRx™
August 26, 2020
Cardiol Therapeutics Appoints CNBC Market Analyst Steven Grasso as Business Advisor
June 29, 2020
David Elsley Files Early Warning Report for Cardiol Therapeutics
June 25, 2020
Cardiol Therapeutics Closes $17.25 Million Bought Deal Offering, Including Full Exercise of the Over-Allotment Option
June 04, 2020
Page 1 of 7
1
2
3
4
5
...
»
Last »
